首页> 外文期刊>Annals of clinical biochemistry. >Radioimmunoassay for the measurement of thrombospondin in plasma and breast cyst fluid: validation and clinical application.
【24h】

Radioimmunoassay for the measurement of thrombospondin in plasma and breast cyst fluid: validation and clinical application.

机译:放射免疫法测定血浆和乳腺囊肿液中血小板反应蛋白的含量:验证和临床应用。

获取原文
获取原文并翻译 | 示例
           

摘要

Thrombospondin is an adhesive protein that has been implicated in malignancy, specifically in tumour progression and angiogenesis. We developed a radioimmunoassay for the measurement of thrombospondin in plasma and breast cyst fluid. The assay exhibited high accuracy, with recoveries of 102-136% and acceptable imprecision, with an intra-assay coefficient of variation (CV) of <7.5% across the analytical range 30-1000 ng/mL and inter-assay CV of 4.4% and 7.7% at 152 and 224 ng/mL, respectively. Thrombospondin measured in the breast cyst fluid of patients with gross cystic disease of the breast showed that patients with type II (Na+) cysts had significantly higher concentrations than type I (K+) cysts. The plasma thrombospondin reference range was determined as 131-274 ng/mL. Patients with breast cancer had significantly higher plasma thrombospondin concentrations than normal individuals or patients with benign breast disease. Plasma thrombospondin was higher in breast cancer patients with lymph node involvement.
机译:血小板反应蛋白是一种粘附蛋白,与恶性肿瘤有关,特别是与肿瘤进展和血管生成有关。我们开发了一种放射免疫测定法,用于测定血浆和乳腺囊肿液中的血小板反应蛋白。该测定法显示出很高的准确性,回收率在102-136%之间,可接受的不精确度,在30-1000 ng / mL的分析范围内,测定内变异系数(CV)<7.5%,测定间CV为4.4%浓度分别为152和224 ng / mL时为7.7%。在患有乳腺囊性疾病的患者的乳腺囊液中测量的血小板反应蛋白显示,II型(Na +)囊肿的患者的血药浓度明显高于I型(K +)囊肿。血浆血小板反应蛋白参考范围确定为131-274 ng / mL。乳腺癌患者的血浆血小板反应蛋白浓度明显高于正常人或乳腺良性疾病患者。淋巴结受累的乳腺癌患者血浆血小板反应蛋白更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号